https://scholars.lib.ntu.edu.tw/handle/123456789/568620
標題: | Viral hepatocarcinogenesis: From infection to cancer | 作者: | Tan A. Shiou-Hwei Yeh CHUN-JEN LIU Cheung C. PEI-JER CHEN |
公開日期: | 2008 | 出版社: | Blackwell Publishing Ltd | 卷: | 28 | 期: | 2 | 起(迄)頁: | 175-188 | 來源出版物: | Liver International | 摘要: | Hepatocellular carcinoma (HCC) is a worldwide health issue that has started receiving attention but is still poorly understood. However, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) are known to be two major causative agents of HCC. They differ in their modes of infection, their treatment options, their genomes and their carcinogenic abilities. However, both share a link with HCC through alterations of the host genome. In order to continue in our search for the mechanisms behind viral hepatocarcinogenesis, the individual entities (HBV, HCV, HCC and host), their natural history, treatment options and genomic properties must be further understood. Additionally, an understanding of the genomics, the link between the entities, is crucial for the success of the ongoing search for therapeutic options for HCC. Similar to most types of cancer, hepatocarcinogenesis is a multistep process involving different genetic alterations that ultimately lead to malignant transformation of the hepatocyte. As technology advances and research continues, the genetic changes and influences among these entities will prove essential to improved diagnostic and therapeutic options. It remains a challenge to provide a clear picture of the connection between virus and cancer. We review (i) the epidemiological link between HBV/HCV infection to HCC; (ii) prevention and control of chronic hepatitis B or C in reducing HCC risk; and (iii) genetic characters of viruses and hosts and the mechanisms associated with HCC susceptibilities, with the intention of providing a direction for future research and treatment. ? 2008 The Authors. Journal compilation ? 2008 Blackwell Munksgaard. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984552538&doi=10.1111%2fj.1478-3231.2007.01652.x&partnerID=40&md5=9e22ce514500e67c84ff324b50c9549b https://scholars.lib.ntu.edu.tw/handle/123456789/568620 |
ISSN: | 1478-3223 | DOI: | 10.1111/j.1478-3231.2007.01652.x | SDG/關鍵字: | entecavir; hepatitis B vaccine; interferon; lamivudine; microRNA; peginterferon alpha; peginterferon alpha2a; recombinant interferon; ribavirin; virus RNA; antiviral activity; cancer risk; cancer susceptibility; chromosomal instability; chromosome aberration; clinical trial; epigenetics; gene mutation; genomics; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; liver carcinogenesis; liver cell carcinoma; malignant transformation; nonhuman; pathophysiology; review; risk reduction; treatment planning; viral genetics; virus carcinogenesis; virus genome; virus load; virus replication; virus virulence |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。